Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

35.5%

104 terminated/withdrawn out of 293 trials

Success Rate

56.8%

-29.7% vs industry average

Late-Stage Pipeline

1%

2 trials in Phase 3/4

Results Transparency

98%

134 of 137 completed trials have results

Key Signals

33 recruiting134 with results78 terminated26 withdrawn

Enrollment Performance

Analytics

Phase 2
119(44.4%)
Phase 1
88(32.8%)
N/A
54(20.1%)
Early Phase 1
5(1.9%)
Phase 3
2(0.7%)
268Total
Phase 2(119)
Phase 1(88)
N/A(54)
Early Phase 1(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (293)

Showing 20 of 293 trials
NCT06584929Not ApplicableRecruiting

Rural Smoking Cessation

Role: lead

NCT05973656Not ApplicableRecruiting

Role of Acetaldehyde in the Development of Oral Cancer

Role: lead

NCT07008638Phase 1Recruiting

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Role: lead

NCT06594445Phase 1Recruiting

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Role: lead

NCT06295757Not ApplicableActive Not Recruiting

Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures

Role: lead

NCT03946423Not ApplicableWithdrawn

BAriaTric Surgery After Breast Cancer Treatment (BATS)

Role: lead

NCT06544811Not ApplicableRecruiting

American Indian Smokefree Native RCT

Role: lead

NCT07070726Recruiting

UNTOLD Ovarian Cancer Unmet Needs Survey

Role: lead

NCT05805605Phase 2Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Role: lead

NCT01666080Not ApplicableRecruiting

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

Role: lead

NCT06377540Phase 2Recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Role: lead

NCT03314974Phase 2Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Role: lead

NCT04003805Phase 1Active Not Recruiting

Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users

Role: lead

NCT07661017Not ApplicableNot Yet Recruiting

GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer

Role: lead

NCT06030648Phase 1Suspended

MT2022-01: MSCs for ALD

Role: lead

NCT01652092Not ApplicableActive Not Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Role: lead

NCT06872333Phase 2Recruiting

Allo HSCT for High Risk Hemoglobinopathies

Role: lead

NCT06412497Phase 2Recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Role: lead

NCT05363267Phase 1Active Not Recruiting

NF-1, Nutraceutical Intervention

Role: lead

NCT03934840Phase 2Completed

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Role: lead